Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents' mechanisms of action and provided prognostic information for untreated myeloma patients on Total Therapy 2 (TT2). Bortezomib was added in Total Therapy 3 (TT3),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shaughnessy, John D., Qu, Pingping, Usmani, Saad, Heuck, Christoph J., Zhang, Qing, Zhou, Yiming, Tian, Erming, Hanamura, Ichiro, van Rhee, Frits, Anaissie, Elias, Epstein, Joshua, Nair, Bijay, Stephens, Owen, Williams, Ryan, Waheed, Sarah, Alsayed, Yazan, Crowley, John, Barlogie, Bart
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186329/
https://ncbi.nlm.nih.gov/pubmed/21628408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-12-328252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados